CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.
Department of Orthopedics, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Nano Lett. 2021 Mar 10;21(5):2224-2231. doi: 10.1021/acs.nanolett.0c05039. Epub 2021 Feb 17.
Messenger RNA (mRNA) vaccine is a promising candidate in cancer immunotherapy as it can encode tumor-associated antigens with an excellent safety profile. Unfortunately, the inherent instability of RNA and translational efficiency are major limitations of RNA vaccine. Here, we report an injectable hydrogel formed with graphene oxide (GO) and polyethylenimine (PEI), which can generate mRNA (ovalbumin, a model antigen) and adjuvants (R848)-laden nanovaccines for at least 30 days after subcutaneous injection. The released nanovaccines can protect the mRNA from degradation and confer targeted delivering capacity to lymph nodes. The data show that this transformable hydrogel can significantly increase the number of antigen-specific CD8 T cells and subsequently inhibit the tumor growth with only one treatment. Meanwhile, this hydrogel can generate an antigen specific antibody in the serum which in turn prevents the occurrence of metastasis. Collectively, these results demonstrate the potential of the PEI-functionalized GO transformable hydrogel for effective cancer immunotherapy.
信使 RNA(mRNA)疫苗是癌症免疫疗法中极具前景的候选者,因为它可以编码肿瘤相关抗原,具有极佳的安全性。然而,RNA 的固有不稳定性和翻译效率是 RNA 疫苗的主要限制因素。在这里,我们报告了一种由氧化石墨烯(GO)和聚乙烯亚胺(PEI)形成的可注射水凝胶,它可以在皮下注射后至少 30 天内生成负载 mRNA(卵清蛋白,一种模型抗原)和佐剂(R848)的纳米疫苗。释放的纳米疫苗可以防止 mRNA 降解,并赋予其靶向淋巴结的输送能力。数据表明,这种可转化水凝胶可以在单次治疗后显著增加抗原特异性 CD8 T 细胞的数量,并随后抑制肿瘤生长。同时,这种水凝胶可以在血清中产生针对特定抗原的抗体,从而防止转移的发生。总之,这些结果表明,PEI 功能化 GO 可转化水凝胶在癌症免疫治疗中有很大的潜力。